Dipeptidyl peptidase IV (DPP-IV) Inhibitors

Summary

Product description

The Competitive Intelligence Report Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors as of November 2008 provides a competitor analysis in the development pipeline of novel DPP-IV inhibitors for treatment of type 2 diabetes.

Dipeptidyl peptidase IV (DPP-IV) inhibitors are a new approach to the treatment of type 2 diabetes. The efficacy of DPP-IV inhibitors is mediated primarily via stabilization of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Incretin action is very brief and is terminated by their breakdown by the enzyme dipeptidyl peptidase-IV (DPP-IV). Merck & Co has introduced the first DPP-IV inhibitor for treatment of type 2 diabetes. Sitagliptin already posted in its second year after the first launch 2007 global sales of US$ 754 mln demonstrating a quite enthusiastic acceptance by the market. Although the FDA raised the bar for approval of new DPP-IV inhibitors by requesting more clinical data from Novartis before approving vildagliptin, this has not deterred competitors from pursuing development of novel DPP-IV inhibitors. At least 17 different molecules are currently in clinical development and further are to follow.

The report provides a compilation of current active projects in research and development of novel DPP-IV inhibitors. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

Contents

• Index
  • DPP-IV Inhibitors
  • Corporate DPP-IV Inhibitor R&D Pipelines
  • About La Merie